# EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB

> **NCT05719389** · — · UNKNOWN · sponsor: **IRCCS San Raffaele** · enrollment: 250 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases
- Rheumatologic Disease

## Interventions

- **DRUG:** CT-P13

## Key facts

- **NCT ID:** NCT05719389
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-14
- **Primary completion:** 2023-10-20
- **Final completion:** 2025-04-20
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05719389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05719389, "EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05719389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*